Hydrea is still considered by many practitioners as the first choice therapy for ET and PV:
Patients treated with HU had a significantly higher risk of developing all second malignancies..
onlinelibrary.wiley.com/doi...
And
pubmed.ncbi.nlm.nih.gov/247...
This again shows the great need for better treatment of MPN..